Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol 2015; 12(2): 91-102Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12(2):91-102.Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treat- ment of cardiac...
Cardiac amyloidosis is caused by the extracellular, interstitial deposition of misfolded protein deposits or amyloid fibrils that result in a restrictive cardiomyopathy with associated conduction system and rhythm disturbances. This family of diseases has distinct prognoses and treatment options depending on ...
Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis Transthyretin cardiac amyloidosis (ATTR-CA) represents an inexorably progressive and fatal cardiomyopathy. Increased understanding of the underlying pathog... A Ioannou - 《Heart International》 被引量: 0发表: 2024年 Tafamidis thera...
mild reduction of ejection fraction and preservation of ejection fraction treatments related to heart failure, treatment of comorbidities in heart failure patients, diagnosis and treatment of cardiac amyloidosis, the timing of referral to all tertiary hospitals and heart failure specialists, and treatment ...
Cardiac amyloidosis is an archetypal example of restrictive cardiomyopathy, with signs and symptoms of global heart failure and diastolic dysfunction. Independent of the aetiology, cardiac amyloidosis is associated with left ventricular concentric "hypertrophy" (i.e. increased wall thickness), preserved (...
Amyloidosis Cardiac Symptoms Amyloidosis that affects the heart is caused by amyloid deposits on heart tissue that make it harder for the heart to function.8Cardiac amyloidosis will not cause symptoms early on. When symptoms do present, they may include:8 ...
There are novel medications approved for the treatment of hereditary transthyretin amyloidosis (ATTRv), classified as transthyretin (TTR) stabilizers or gene silencers. While many patients may be on both classes of medications, there is no data available on the safety and efficacy of combination ther...
Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. A 58-year-old Japanese woman on hemodialysis (HD) was admitted for intractable rheumatoid arthritis. Even after HD was started due to end-stage renal failu... Y Hattori,Y Ubara,K...
The management of atrial fibrillation can be challenging, because contemporary agents for rate and rhythm control may be poorly tolerated in patients with cardiac amyloidosis. Patients with cardiac amyloidosis also have a high rate of intracardiac thrombus and should be anticoagulated in the presence ...
Credit: Mayo Clinic Amyloidosis occurs when the body produces abnormal proteins that bind together to form a substance called amyloid. Amyloids can deposit in any tissue or organ, including the heart, kidneys, liver and nerves. When it occurs in the heart, it's called cardiac amyloidosis. Dr....